Details of the Drug

General Information of Drug (ID: DMMQ2OW)

Drug Name

Nintedanib

Synonyms

Nintedanib; Vargatef; 656247-17-5; BIBF-1120; Intedanib; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; G6HRD2P839; 1160294-26-7; CHEBI:85164; Nintedanib

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[2]
Ovarian neoplasm	N.A.	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[3]

Affected Organisms

Humans and other mammals

ATC Code

L01EX09: Nintedanib

L01EX: Other protein kinase inhibitors

L01E: PROTEIN KINASE INHIBITORS

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C31H33N5O4
Canonical SMILES: CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O
InChI: InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3
InChIKey: CPMDPSXJELVGJG-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 135423438
ChEBI ID: CHEMBL85164
CAS Number: 656247-17-5
UNII: G6HRD2P839
DrugBank ID: DB09079
TTD ID: D05USQ

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Drug Pharmacogenomic Perturbation (DPP)^NEW

Click to Jump to the Detailed DPP Information of This Drug

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
2	Nintedanib FDA Label
3	ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.